ArticleAI in neuroscience2025
Instantaneous Frequency: A New Functional Biomarker for Dynamic Brain Causal Networks.
Article in AI in neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Background: This study introduces instantaneous frequency (IF) analysis as a novel method for characterizing dynamic brain causal networks from functional magnetic resonance imaging blood-oxygen-level-dependent signals. Methods: Effective connectivity, estimated using dynamic causal modeling, is analyzed to derive IF sequences, with the average IF across brain regions serving as a potential biomarker for global network oscillatory behavior. Results: Analysis of data from the Alzheimer's Disease (AD) Neuroimaging Initiative, Open Access Series of Imaging Studies, and Human Connectome Project demonstrates the method's efficacy in distinguishing between clinical and demographic groups, such as cognitive decline stages (e.g., normal control, early mild cognitive impairment [MCI], late MCI, and AD), sex differences, and sleep quality levels. Conclusion: Statistical analyses reveal significant group differences in IF metrics, highlighting its potential as a sensitive indicator for early diagnosis and monitoring of neurodegenerative and cognitive conditions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.